Henrik Ullits Andersen

List of Publications by Year
in descending order

57	1,861	304602 22	265120 42
papers	citations	h-index	g-index

58	58	58	2376
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pumpâ€treated type 1 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 212-220.	2.2	4
2	Effects of shortâ€acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 221-227.	2.2	5
3	Insulin Pump Treatment in Adults with Type 1 Diabetes in the Capital Region of Denmark: Design and Cohort Characteristics of the Steno Tech Survey. Diabetes Therapy, 2022, 13, 113-129.	1.2	6
4	Relationship between peripheral neuropathy, diastolic function and adverse cardiovascular outcome in individuals with type 1 diabetes mellitus without known cardiovascular disease: Results from the Thousand & 1 Study. Diabetes, Obesity and Metabolism, 2021, 23, 158-165.	2.2	4
5	Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes. Journal of Diabetes, 2021, 13, 754-763.	0.8	2
6	Does nocturnal hypoglycaemia really improve quality of life? Reply to SÃ¸holm U, Broadley MM, Choudhary P et al [letter]. Diabetologia, 2021, 64, 1895-1896.	2.9	0
7	Effects of continuous glucose monitor-recorded nocturnal hypoglycaemia on quality of life and mood during daily life in type 1 diabetes. Diabetologia, 2021, 64, 903-913.	2.9	9
8	Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulinâ€pumpâ€treated patients with type 1 diabetes: The Lira Pump trialâ€”a randomized, doubleâ€blinded, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 492-500.	2.2	29
9	Effect of shortâ€acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized doubleâ€blind placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 1639-1647.	2.2	3
10	Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 313-324.	5.5	39
11	Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: the Thousand & 1 Study. European Journal of Endocrinology, 2020, 182, 481-488.	1.9	10
12	Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study. Diabetologia, 2019, 62, 2354-2364.	2.9	23
13	The dietary education trial in carbohydrate counting (DIET-CARB Study): study protocol for a randomised, parallel, open-label, intervention study comparing different approaches to dietary self-management in patients with type 1 diabetes. BMJ Open, 2019, 9, e029859.	0.8	13
14	Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. Frontiers in Endocrinology, 2019, 10, 242.	1.5	5
15	Breastfeeding at night is rarely followed by hypoglycaemia in women with type 1 diabetes using carbohydrate counting and flexible insulin therapy. Diabetologia, 2019, 62, 387-398.	2.9	21
16	Prevalence of heart failure and the diagnostic value of MRâ€proANP in outpatients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 736-740.	2.2	16
17	Assessment of diurnal melatonin, cortisol, activity, and sleepâ^'wake cycle in patients with and without diabetic retinopathy. Sleep Medicine, 2019, 54, 35-42.	0.8	20
18	Hypoglycemic Exposure and Risk of Asymptomatic Hypoglycemia in Type 1 Diabetes Assessed by Continuous Glucose Monitoring. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2329-2335.	1.8	39

#	Article	IF	Citations
19	Treatment Modalityâ€“Dependent Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes: Danish Adult Diabetes Database Study. Diabetes Technology and Therapeutics, 2018, 20, 229-234.	2.4	16
20	Six-Year Follow-Up After Insulin Pump Initiation: HbA1c Is Significantly Reduced Without Weight Gain. Journal of Diabetes Science and Technology, 2018, 12, 535-536.	1.3	3
21	Type 1 diabetes is associated with T-wave morphology changes. The Thousand & 1 Study. Journal of Electrocardiology, 2018, 51, S72-S77.	0.4	6
22	Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial. BMJ Open, 2018, 8, e021861.	0.8	3
23	Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 734-738.	2.2	16
24	Changes in HbA1c and Weight Following Transition to Continuous Subcutaneous Insulin Infusion Therapy in Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2017, 11, 83-86.	1.3	16
25	Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: <scp>A</scp> randomized, placeboâ€controlled, doubleâ€blind, parallelâ€group study. Diabetes, Obesity and Metabolism, 2017, 19, 773-782.	2.2	28
26	Retinopathy is associated with impaired myocardial function assessed by advanced echocardiography in type 1 diabetes patients â€“ The Thousand & 1 Study. Diabetes Research and Clinical Practice, 2016, 116, 263-269.	1.1	9
27	Early myocardial impairment in type 1 diabetes patients without known heart disease assessed with tissue Doppler echocardiography: The Thousand & 1 study. Diabetes and Vascular Disease Research, 2016, 13, 260-267.	0.9	13
28	Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics. Diabetes and Vascular Disease Research, 2016, 13, 321-330.	0.9	42
29	Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 221-232.	5.5	127
30	Cardiac time intervals and the association with 2D-speckle-tracking, tissue Doppler and conventional echocardiography: the Thousand&1 Study. International Journal of Cardiovascular Imaging, 2016, 32, 789-798.	0.7	8
31	Statins are independently associated with increased HbA1c in type 1 diabetes â€“ The Thousand & 1 Study. Diabetes Research and Clinical Practice, 2016, 111, 51-57.	1.1	12
32	Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. BMJ Open, 2015, 5, e007791-e007791.	0.8	12
33	Global Longitudinal Strain IsÂNotÂImpairedÂin Type 1 Diabetes PatientsÂWithout Albuminuria. JACC: Cardiovascular Imaging, 2015, 8, 400-410.	2.3	86
34	Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study. Diabetes Care, 2015, 38, 2250-2257.	4.3	91
35	Changes in basal rates and bolus calculator settings in insulin pumps during pregnancy in women with type 1 diabetes. Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 724-728.	0.7	41
36	Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study. Diabetologia, 2014, 57, 672-680.	2.9	71

#	Article	IF	Citations
37	Severe hypoglycemia in pregnant women with type 2 diabetesâ€"A relevant clinical problem. Diabetes Research and Clinical Practice, 2013, 102, e17-e18.	1.1	9
38	No Effect of Periodic Continuous Glucose Monitoring on Hemoglobin A1c in Poorly Regulated Type 1 Patients. Journal of Diabetes Science and Technology, 2013, 7, 802-803.	1.3	0
39	Total Mortality by Elevated Transferrin Saturation in Patients With Diabetes. Diabetes Care, 2013, 36, 2646-2654.	4.3	13
40	The Effect of Real-Time Continuous Glucose Monitoring in Pregnant Women With Diabetes. Diabetes Care, 2013, 36, 1877-1883.	4.3	172
41	RNA modifications by oxidation: A novel disease mechanism?. Free Radical Biology and Medicine, 2012, 52, 1353-1361.	1.3	174
42	Elevated Transferrin Saturation and Risk of Diabetes: Three population-based studies. Diabetes Care, 2011, 34, 2256-2258.	4.3	60
43	Cystic Fibrosis-Related Diabetes: The presence of microvascular diabetes complications. Diabetes Care, 2006, 29, 2660-2663.	4.3	73
44	Interferon-Î³ Induces Interleukin-1 Converting Enzyme Expression in Pancreatic Islets by an Interferon Regulatory Factor-1-Dependent Mechanism1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 830-836.	1.8	49
45	GLUTATHIONE DEPLETION INHIBITS IL-1Î²-STIMULATED NITRIC OXIDE PRODUCTION BY REDUCING INDUCIBLE NITRIC OXIDE SYNTHASE GENE EXPRESSION. Cytokine, 2000, 12, 1391-1394.	1.4	21
46	Absence of toxicity associated with adenoviral-mediated transfer of the Î²-galactosidase reporter gene to neonatal rat islets in vitro. Diabetes Research and Clinical Practice, 1999, 44, 157-163.	1.1	9
47	Interleukin-1Î²-induced Rat Pancreatic Islet Nitric Oxide Synthesis Requires Both the p38 and Extracellular Signal-regulated Kinase 1/2 Mitogen-activated Protein Kinases. Journal of Biological Chemistry, 1998, 273, 15294-15300.	1.6	145
48	DEXAMETHASONE PREVENTS INTERLEUKIN-1Î²-MEDIATED INHIBITION OF RAT ISLET INSULIN SECRETION WITHOUT DECREASING NITRIC OXIDE PRODUCTION. Cytokine, 1997, 9, 563-569.	1.4	8
49	Interleukin-1Î² induced changes in the protein expression of rat islets: A computerized database. Electrophoresis, 1997, 18, 2091-2103.	1.3	52
50	Interleukin-1Î²-induced nitric oxide production from isolated rat islets is modulated by D-glucose and 3-isobutyl-1-methyl xanthine. European Journal of Endocrinology, 1996, 134, 251-259.	1.9	32
51	Cytokines and the endocrine system. I. The immunoendocrine network. European Journal of Endocrinology, 1995, 133, 660-671.	1.9	66
52	Two-Dimensional Gel Electrophoresis of Rat Islet Proteins: Interleukin 1Â-Induced Changes in Protein Expression are Reduced by L-Arginine Depletion and Nicotinamide. Diabetes, 1995, 44, 400-407.	0.3	40
53	Nicotinamide treatment in the prevention of insulinâ€dependent diabetes mellitus. Diabetes/metabolism Reviews, 1993, 9, 295-309.	0.4	41
54	ERRATUM Genetically determined differences in newborn rat islet sensitivity to interleukin-1 in vitro: no association with the diabetes prone phenotype in the BB-rat. European Journal of Endocrinology, 1989, 120, 400.	1.9	0

#	Article	IF	Citations
55	Genetically determined differences in newborn rat islet sensitivity to interleukin-1 in vitro: no association with the diabetes prone phenotype in the BB-rat. European Journal of Endocrinology, 1989, 120, 92-98.	1.9	8
56	Interleukin 1 induces new protein formation in isolated rat islets of Langerhans. European Journal of Endocrinology, 1989, 121, 136-140.	1.9	28
57	Modulation of calciumflux influences interleukin 1 Î² effects on insulin release from isolated islets of Langerhans. European Journal of Endocrinology, 1989, 121, 447-455.	1.9	13